Short Interest in iCAD, Inc. (NASDAQ:ICAD) Expands By 20.1%

iCAD, Inc. (NASDAQ:ICAD - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 269,400 shares, an increase of 20.1% from the March 15th total of 224,300 shares. Based on an average trading volume of 459,200 shares, the days-to-cover ratio is presently 0.6 days. Currently, 1.0% of the company's stock are short sold.

Hedge Funds Weigh In On iCAD

Institutional investors and hedge funds have recently made changes to their positions in the stock. First Eagle Investment Management LLC grew its position in iCAD by 6.1% during the fourth quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company's stock worth $1,311,000 after buying an additional 41,000 shares during the period. Geode Capital Management LLC boosted its stake in shares of iCAD by 6.6% during the 4th quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company's stock worth $506,000 after acquiring an additional 17,059 shares in the last quarter. Perritt Capital Management Inc boosted its stake in shares of iCAD by 1.9% during the 4th quarter. Perritt Capital Management Inc now owns 189,100 shares of the technology company's stock worth $346,000 after acquiring an additional 3,600 shares in the last quarter. Summit Trail Advisors LLC acquired a new stake in shares of iCAD in the 4th quarter worth approximately $214,000. Finally, Granahan Investment Management LLC purchased a new position in iCAD in the 4th quarter valued at approximately $96,000. 24.61% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Craig Hallum cut iCAD from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 16th. Laidlaw reaffirmed a "hold" rating on shares of iCAD in a report on Thursday, April 17th. StockNews.com started coverage on shares of iCAD in a research note on Saturday. They issued a "sell" rating on the stock. Finally, BTIG Research downgraded shares of iCAD from a "buy" rating to a "neutral" rating in a research report on Wednesday, April 16th.

iCAD Trading Down 0.6 %

Shares of NASDAQ:ICAD traded down $0.02 during midday trading on Friday, hitting $3.28. The stock had a trading volume of 464,025 shares, compared to its average volume of 373,447. iCAD has a 1 year low of $1.18 and a 1 year high of $3.78. The stock has a 50 day moving average price of $2.33 and a two-hundred day moving average price of $2.20. The company has a market capitalization of $89.76 million, a PE ratio of -25.23 and a beta of 1.78.

iCAD (NASDAQ:ICAD - Get Free Report) last announced its quarterly earnings data on Wednesday, March 19th. The technology company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.02. The company had revenue of $5.41 million for the quarter, compared to analyst estimates of $4.72 million. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.